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1133-139 Low Dose Of Propranolol Prevents the Development of 
Heart Failure by Restoring the Defective Interaction of 
FKBP12.6 With Cardiac Ryanodine Receptor 
Masahiro Doi, Masafumi Yano, Shigeki Kobeyashi, Masateru Kohno, Masae Suetsugu, 
Takahiro Tokuhisa, Shin-ichi Okuda, Tomoko Ohkusa, Michihire Kohno, Masunori 
Matsuzaki, Yamaguchi University, Ube, Japan. 
Background. In head failure, hyperphosphorylation of ryanodine receptor (RyR) medi- 
ated through PKA has been shown to cause dissociation of FKBP12.6 from RyR, result- 
ing in an abnormal Ca 2+ leak through RyR and possibly consequent cardiac dysfunction. 
Here, we assessed whether ~-blookede can restore this defective channel function of 
RyR and therefore improve cardiac function in heart failure. Methods and Results, Sar- 
coplasmic retioulum (SR) was isolated from dog LV muscles {normal (N), n=5; 4-weeks 
RV pacing with or without propranolol [P(+): n=4, P(-): n=5, respectively]}. In normal 
dogs, the dose of propranolol (0.05 mg/kg/day, iv) decreased head rate at baseline by 14 
%, but did not attenuate the isoproterenol (0.8 pg/kg/min)-induced increase in peak +dP/ 
dt of LV pressure. 1) As compared with pre-RV pacing, both end-diastolic [36.2mm in 
P(+) versus 41.9mm in P(-), p<0.05] and end-systolic diameter [29.4mm in P(+) versus 
37.5mm in P(-), p<0.05] were less increased in P(+) than P(-), associated with lesser 
decrease in fractional shortening [19.0% in P(+) versus 10.2% in P(-), p<0.05]. 2) In SR 
from P(-), a prominent Ca 2+ leak was observed and FK506 that dissociates FKBP12.6 
from RyR did not induce further Ca 2+ leak because of a partial loss of FKBP12.6 from 
RyR. However, there was no appreciable Ca 2+ leak in SR from P(+), and FK506-inducad 
Ca 2+ leak was elicited like normal SR. 3) RyR was labeled in a sita-directed fashion with 
the fluorescent conformational probe methylcoumadn acetate (MCA). In SR from P(+), 
the FK506-inducad increase in MCA fluorescence, which was virtually absent in SR from 
P(-), was observed like in normal SR. 4) Indeed, both stoichiometry of FKBP12.6 versus 
RyR assessed by [3H]FKS06 and [3H]ryanodine-binding assays [3.6 : 1 in N, 1.1 : 1 in P(- 
), 2.4 : 1 in P(+); p<0.05] and protein expression of FKBP12.6 assessed by Western Blot 
analysis were restored towards those in normal SR. 
Conclusions. Low dose of propranolol attenuated LV remodeling presumably by amelio- 
rating the defective interaction of FKBP12.6 with RyR, presumably resulting in an inhibi- 
tion of intracallular Ca 2+ overload and hence a prevention of the development of heart 
failure. 
1133-140 Chronic Therapy With Metoprolol CR/XL Prevents 
Apoptosis Inducing Factor and Downregulates the Pro- 
Apoptotic Protein Bak in Card iomyocytes  of  Dogs With 
Heart  Fai lure 
Anastassia V, Todor, Victor G. Sharov, George Suzuki, Hideaki Modta, Sidney Goldstein, 
Hani N. Sabbah, Henry Ford Health System, Detroit, Michigan. 
Background: Chronic therapy with beta-adrenergic receptor antagonists in heart failure 
(HF) has been shown to attenuate cardiomyocyte apeptosis. We previously showed that 
beta-blockers also downregulate the expression of active caspase-3, a key enzyme that 
promotes nuclear DNA fragmentation, a hallmark of programmed cell death. Activation of 
caspase-3 is regulated, in part, by apeptosis inducing factor (AIF), a mitochonddal pro- 
tein, which is activated by pro-apoptotic members of the Bcl-2 family that include Bak. In 
the present study, we examined the effects of chronic therapy with metoprotol CR/XL 
(ToproI-XL) on the expression of AtF and Bak in cardiomyocytes of dogs with chronic HF. 
Methods: HF was produced in 14 dogs by intracoronary microemboiizations. Dogs were 
randomized to 3 months of monotherapy with Toprol-XL (100 mg once daily, n=7) or to no 
therapy at all (control, n=7). At the end of 3 months of therapy, dogs were sacrificed, and 
cardiomyocytes were enzymatically isolated from the LV free wall. Cardiomyocytes were 
also isolated from the LV free wall of 5 normal (NL) dogs and were used for comparisons. 
Expression of AIF was examined with Western blots using cytosolic fraction prepared 
from cardiomyocyte homogenate. Expression of Bak was also examined with Western 
blots using cardiomyocyte homogenate. Bands were quantified in densitometric units. 
Results: Expression of Bak was significantly increased in cardiomyocytes isolated from 
untreated HF dogs compared to NL (6.3 + 0.6 vs. 0.5 + 0.1, P<0.05). Treatment with 
ToproI-XL significantly decreased the expression of Bak (1.7 + 0.24) compared to 
untreated controls (P<0.05). Expression of AIF was significantly increased in cardiomyo- 
cytes isolated from untreated HF dogs compared to NL (6.3 _+ 0.4 vs. 4.3 + 0.2, P<0.05). 
Treatment with ToproI-XL significantly decreased the expression of AIF (3.1 _+ 0.5) com- 
pared to untreated control (P<0.05). 
Conclusions: AIF and Bak are upregulatad in cardiomyocytes of dogs with HF. Chronic 
therapy with Toprol-XL attenuates the upregulation of both AIF and Bak. These data pro- 
vide further support that long-term therapy with beta-blockers limits apoptosis-mediated 
ongoing cardiomyocyte loss in HF. 
1133-161 Negative Modulation of Beta3-Adrenergic St imulat ion  
on Cardiomyocyte Contractile Performance and [Ca2+]i  
Regulation Before and After Heart Failure: Insights Into 
the Underlying Cellular Mechanisms 
Che-Pino Cheno. Katsuya Onishi, Heng-Jie Chang, Zhu-Shan Zhang, Tomohiko Ukai, 
Hiroshi Hasegawa, Wake Forest University School of Medicine, Winston-Salem, North 
Carolina. 
Background: We have previously reported that ~3-adrenergic receptor (AR) stimulation 
produces direct inhibition on LV contraction in conscious dogs before and after pacing- 
induced heart failure (CHF). 
Methods: To define the cellular mechanism, we assessed cell contraction, relaxation, 
[Ca2+]i transient and Ca 2+ current (ICa,L) responses to BRL-37344 (BRL), a ~3-AR ago- 
nist in freshly isolated LV cardiomyocytes obtained from 7 instrumented dogs before and 
after pacing-induced CHF. 
Results: In normal myocytes, BRL (10"8M) caused significant decrease in cell contrac- 
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tion measured as the percent shortening (SA, -29%, 9.1 vs 12.9%), the peak velocity 
shortening (dL/dtmax, -13%, 164.3 vs 189.3 ~m/sec) and reiengthening (dR/dtma x, -17%, 
122.1 vs 146.3 I~m/sec) with parallel decreases in [Ca2+]l transient (-22%, 277.2 vs 331.3 
nM) and ICa,L (-25%, 2.7 VS 3.6 pA/pF). In CHF myocytes, BRL produced much greater 
decreases in cell contraction and relaxation (SA, -46%, 4.1 vs 7.6%; dlJdtma x, -25%, 
63.3 vs 64.7 Am/sec; dR/dtmax, -24%, 67.1 vs 88.4 Am/sec) with associated significantly 
greater reductions in peak [Ca2+] i transient (-32%, 181.3 vs 270.1 nM) and ICa,L (-37%, 
2.0 vs 3.2 pA/pF). These BRL-induced responses were not modified by pretreating myo- 
cytes with nadolol (10"5M), a ~1- and ~2-AR antagonist, but were prevented by bupranolol 
(10"aM), a ~3-antagonist. These responses were also nearly abolished by pretreating 
myocytes with PTX (2 ~g/ml, 6 hrs, 36°C) and dibutyryl-cAMP (5x10-4M). In contrast, 
BRL-induced decrease in SA (-12% vs -29%) was significantly attenuated by pretreat- 
ment with NOS inhibitor, L-NAME (10"4M, 30 min), but the BRL caused decreases in 
[Ca2+]i transient and ICa,L were not significantly altered. 
Conclusion: 133-AR stimulation produces negative inotropic action in both normal and 
CHF myocytes due to decreased [Ca2+]i transient, ICe,L, and myocyte Ca 2+ sensitivity. 
These effects are likely to be mediated through both NO-cAMP dependent and NOS- 
independent mechanisms that is coupled with PTX-sensitive G protein pathway and may 
involve a decreased level of cAMP. 
1133-162 The Putat ive Beta Four-Adrenergic Receptor Is e Novel 
State of  the  Beta One-Adrenergic Receptor 
Clive J. Lewis, Haibin Gong, Walter J. Koch, Mords J. Brown, Harding E. Sian, Clinical 
Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, 
United Kingdom, Cardiac Medicine, National Heart and Lung Institute, Imperial Coflege 
School of Medicine, London, United Kingdom. 
Background: In human cardiac tissue, there is evidence from functional, second mes- 
senger and radioligand binding studies of a novel Gs-coupled third cardiostimulatory 
receptor: the putative beta 4-adrenoceptor (~4AR). ~4AR effects are defined by the non- 
conventional partial agonist CGP 12177 (CGP) and include positive inotropy, lusitropy 
and chronotropy in head. Recent evidence suggests that the ~4AR may be a novel con- 
formation of the 131AR protein. We have examined the effect of ~IAR overexpression in 
adult rat cardiomyocytes on the inotropic responses of isoprenaline (ISO) and CGP. 
Methods: Myocytes were transfected with adenovirus containing sequence for the 
human 131AR. ~IAR density was measured by [1251]-iodocyanopindolol binding to ven- 
tricular myooyte membranes. Inotropic responses to ISO and CGP (in the presence of 
propranolol) were studied 48 h after transfection by measuring cell shortening in electri- 
cally stimulated ventrioular myocytes. 
Results: Binding confirmed an 18-fold increase in ventricular ~IAR density. There was a 
parallel left shift of the concentration-respense curve (CRC) to ISO (control EC50 19nM 
(n=21), ~IAR transfected 1.7nM (n=20), p<0.0005). There was also a left shift of CRC to 
CGP (EC50 595nM (n=16) and 69.8nM (n=22) respectively, p<0.005) as well as an 
increase in maximum response. 
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Conclusions: The similar magnitude of the decreases in EC50 to ISO and CGP follow- 
ing ~,IAR overexprassion further supports the hypothesis that the ~4AR is a novel confor- 
mation of the ~,IAR. 
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1134-146 Bone Loss end Prevention of Osteoporoeie in 
Congestive Heart Fai lure 
Robed J. Frost. Carolin Sonne, Walter Rambeck, Karl Theisen, Roland G&rtner, Hans- 
Ulrich Stampfle, University of Munich-Med. Klinik Innenstadt, Depts. of Cardiology and 
Endocdnology, Munich, Germany 
Background: Cross sectional studies have shown that more than 50 % of the patients 
(pts.) with congestive heart failure (CHF) have decreased bone mineral density (BMD). 
There is limited knowledge about the longitudinal changes of BMD and no prevention 
studies of ostaoperosis in pts. with CHF. Methods: The present study was a prospective, 
longitudinal, randomized thai in which 34 pts. with CHF were assigned to 1000rag cal- 
cium supplementation (17m; 51,1±9,1 years; EF 32±12%) or no osteoporosis prevention 
therapy (15m,2w; 48,6±11,9 years; EF 29±9%). BMD (g/cm2; t- and z-score) was mea- 
sured at lumbar spine (LS) and femoral neck (FN) by dual-energy-X-ray-absorptiometry 
(Lunar Expert) at baseline and after 12 months. Fractures were assessed by X-ray of 
chest, thoracic and lumbar spine. Biochemical analysis included parameters of calcium 
metabolism, renal function, gonadal hormones and intact parathyroid hormone (iPTH). 
Results: Ostaopenia (41% in the LS, 35% in the FN) and osteoporosis (15 % in the LS, 6 
% in the FN) were frequently seen in these pts., 47% of the pts. showed an impaired 
renal function, 30% a secondary hyperparathyroidism and 32% a hypogonadism. Pts. 
